Moneycontrol.com | FDA Approves Lenalidomide for the Treatment of Mantle Cell Lymphoma OncLive The MCL-001 study enrolled 134 patients with MCL who had received prior treatment with rituximab, cyclophosphamide, an anthracycline (or mitoxantrone), and bortezomib alone or in combination and who had documented relapsed or refractory disease. Celgene Corporation gets USFDA approves for REVLIMID FDA clears Celgene's sNDA for mantle cell lymphoma drug candidate Revlimid Gains New Lymphoma Indication |
